Gilead Sciences Inc. reported strong business performance, highlighting a 4% year-over-year increase in base business sales, or nearly 8% growth when excluding the impact from Medicare Part D redesign. The company achieved fourth quarter total product sales, excluding Veklury, of 7.7 billion, marking a 7% increase year-over-year and 9% sequentially, driven primarily by higher sales across HIV and Livdelzi. Including Veklury sales of 212 million, total product sales reached 7.9 billion, up 5% year-over-year and 8% sequentially. Gilead emphasized the durability of its core business and sustained launch momentum, with up to 10 ongoing and potential new product launches through 2027. With no major product loss of exclusivity expected until 2036, Gilead stated it is well-positioned for both near-term and long-term growth. The full report can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief on February 10, 2026, and is solely responsible for the information contained therein.